ABSTRACT
Objectives To examine the associations between catheter ablation treatment (CA) versus medical management and cognitive impairment among older adults with atrial fibrillation (AF).
Methods Ambulatory patients who had AF, were ≥ 65-years-old, and were eligible to receive oral anticoagulation could be enrolled into the SAGE (Systematic Assessment of Geriatric Elements)-AF study from internal medicine and cardiology clinics in Massachusetts and Georgia between 2016 and 2018. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) tool at baseline, one-, and two years. Cognitive impairment was defined as a MoCA score ≤ 23. Multivariate-adjusted logistic regression of longitudinal repeated measures was used to examine associations between treatment with CA vs. medical management and cognitive impairment.
Results 887 participants were included in this analysis. On average, participants were 75.2 ± 6.7 years old, 48.6% women, and 87.4% white non-Hispanic. 193 (21.8%) participants received a CA before enrollment. Participants who had previously undergone CA were significantly less likely to be cognitively impaired during the two-year study period (aOR 0.70, 95% CI 0.50-0.97) than those medically managed (i.e., rate and/or rhythm control), even after adjusting with propensity score for CA. At the two-year follow-up a significantly greater number of individuals in the non-CA group were cognitively impaired (MoCA ≤ 23) compared to the CA-group (311 [44.8%] vs. 58 [30.1%], p=0.0002).
Conclusions In this two-year longitudinal prospective cohort study participants who underwent CA for AF before enrollment were less likely to have cognitive impairment than those who had not undergone CA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by a grant from the National Institutes of Health (R01HL126911).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants enrolled in the study provided their informed written consent for protocols approved by the institutional review boards of the University of Massachusetts Medical School, Boston University, and Mercer University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1 Bahadar S. Srichawla: Email (bahadar.srichawla{at}umassmemorial.org). University of Massachusetts Chan Medical School. 55 Lake Ave N Worcester MA 01655. Tel 508-334-2527.
2 Alexander P. Hamel: Email (alexander.hamel{at}umassmed.edu)
3 Philip Cook: Email (philip.cook{at}umassmemorial.org)
4 Rozaleen Aleyadeh: Email (rozaleen.aleyadeh{at}umassmemorial.org).
5 Darleen Lessard: Email (darleen.lessard{at}umassmed.edu).
6 Edith M. Otabil: Email (edith.mensahotabil{at}umassmed.edu).
7 Jordy Mehawej: Email (Jordy.mehawej{at}umassmed.edu)
8 Jane S. Saczynski: Email (j.saczynski{at}northeastern.edu)
9 David McManus: Email (david.mcmanus{at}umassmed.edu).
10 Majaz Moonis: Email (majaz.moonis{at}umassmemorial.org)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
